SGLT2 inhibition in the management of type 2 diabetes: Potential impact on CVD Risk

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Effects of empaglifozin on kidney outcomes after acute MI
Effects of empaglifozin on kidney outcomes after acute MI
ESC Congress 2024
Effects of empaglifozin on kidney outcomes after acute MI
- Deepak Bhatt, MD
Increasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
Increasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
ACC.24
Increasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
- Alexander J. Blood, MD
Characteristics of patients with DM using icosapent ethyl in the real world
Characteristics of patients with DM using icosapent ethyl in the real world
Hyperlipidemia
Characteristics of patients with DM using icosapent ethyl in the real world
- Om P. Ganda, MD
A practical look at cardiorenal protection for CKD in T2D: Applying recent data
A practical look at cardiorenal protection for CKD in T2D: Applying recent data
Kidney Disease
A practical look at cardiorenal protection for CKD in T2D: Applying recent data
- Carolyn Lam, MD, PhD
- Maria Luiza Caramori, MD, PhD
- Ana Maria Cebrián-Cuenca, MD, PhD
- Pam R. Taub, MD, FACC, FASPC